Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant - Archive ouverte HAL Access content directly
Journal Articles British Journal of Haematology Year : 2021

Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

(1) , (1) , (2) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (2, 1) , (2, 1)
1
2
Benoît Tessoulin
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03542571 , version 1 (25-01-2022)

Identifiers

Cite

Amandine Le Bourgeois, Marianne Coste‐burel, Thierry Guillaume, Pierre Peterlin, Alice Garnier, et al.. Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant. British Journal of Haematology, 2021, pp.10.1111/bjh.17911. ⟨10.1111/bjh.17911⟩. ⟨inserm-03542571⟩
14 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More